Current Appointments & Affiliations
Associate Professor of Medicine
·
2021 - Present
Medicine, Medical Oncology,
Medicine
Member of the Duke Cancer Institute
·
2010 - Present
Duke Cancer Institute,
Institutes and Centers
Recent Publications
Phase II Study of Dabrafenib and Trametinib in Patients With Tumors With BRAFV600E Mutations: Updated Results From NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol H.
Journal Article JCO Precis Oncol · January 2026 PURPOSE: Subprotocol H of the NCI-MATCH trial demonstrated the efficacy of dabrafenib + trametinib in a cohort of patients with BRAFV600-mutated treatment-refractory solid tumors and myeloma. To confirm the longer-term efficacy and safety of this combinati ... Full text Link to item CiteMetastatic Uveal Melanoma Surveillance: A Delphi Panel Consensus.
Journal Article Cancers (Basel) · December 30, 2025 BACKGROUND/OBJECTIVES: Uveal melanoma is a rare but aggressive intraocular malignancy that metastasizes in up to half of patients, most commonly to the liver, despite effective local treatment. In the absence of robust evidence, there are no standardized g ... Full text Link to item CiteAdvanced stage melanoma during pregnancy: recommendations from a retrospective, multicentre, registry-based study.
Journal Article EClinicalMedicine · November 2025 BACKGROUND: Diagnosis and treatment of advanced melanoma during pregnancy represents a major challenge, with scarce data on outcome or management available. Therefore, the Melanoma Pregnancy Taskforce collected real-world data to understand the current man ... Full text Link to item CiteRecent Grants
A Multicenter, Open-Label, Randomized, Controlled Study to Assess the Antitumor Activity of LNS8801 With and Without Pembrolizumab in Patients With Treatment-Refractory, Unresectable Melanoma
Clinical TrialPrincipal Investigator · Awarded by Linnaeus Therapeutics, Inc. · 2025 - 2030A Phase 2 Peri-operative Trial of Fianlimab and Cemiplimab Compared with Pembrolizumab in Patients with Resectable Stage III and IV Melanoma R3767-ONC-2208
Clinical TrialPrincipal Investigator · Awarded by Regeneron Pharmaceuticals, Inc. · 2024 - 2029Replimune RP2-202: A Randomized, Phase 2/3, Open-Label Study to Investigate the Efficacy and Safety of RP2 in Combination with Nivolumab versus Ipilimumab in Combination with Nivolumab in Immune Checkpoint Inhibitor-Naive Adult Patients with Inoperab
Clinical TrialPrincipal Investigator · Awarded by Replimune, Inc. · 2024 - 2029View All Grants
Education, Training & Certifications
University of North Carolina, Chapel Hill ·
2004
M.D.